MedChemComm · 2017 · 22 citations · 25 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoverySynthetic Medicinal ChemistryHeterocyclic ChemistryLead Compound DesignLigand BindingPotency OptimizationTyrosine Kinase Inhibitors[2+2] CycloadditionAlkyne Cycloaddition ReactionsAzide-alkyne Cycloaddition ProbesBioactive HeterocyclesChemical Synthesis Of AnaloguesCycloaddition ReactionsMedicinal Chemistry ApplicationsMedicinal Heterocycles
Alkyne–azide cycloaddition derivatives of DHZ (<bold>1</bold>) were synthesized and screened for cytotoxic potential in which the derivatives, <bold>3</bold>, <bold>6</bold>, <bold>7</bold>, <bold>8</bold>, <bold>9</bold> and <bold>15</bold> displayed most potent with IC<sub>50</sub> value ranging from 1.8–3.0 μM.
25
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Rainy Umbas, William B. Isaacs, P P Bringuier et al. · PubMed · 1994 · 535 citations
Jeremy R. Graff, Bruce W. Konicek, Ann M. McNulty et al. · Journal of Biological Chemistry · 2000 · 380 citations · Full text